hfpef semaglutide Poll: Do you think we'll see new FDA approval for semaglutide, specifically or Heart Failure and/or CKD, in 2025? 💊 This post highlights primary takeaways from 2 major trials from the past ~ Semaglutide versus placebo in people

Patient Success Stories Many patients have experienced transformative results with Semaglutide, reporting better control over their diabetes and significant weight loss achievements

This is often: A BMI of 30 or above for obesity A BMI of 27 or above for overweight if there is at least one weight-related health condition Weight-related conditions can include high blood pressure, raised cholesterol, prediabetes, type 2 diabetes or sleep apnoea

Spatial transcriptomics offers an advanced tool for identifying drug targets

instead, they arise spontaneously during cell division (similar to cancer mutations)

Decreased activity of APC/C leads to increased expression of Cyclin B1 and Skp2, which further mediates podocyte injury[37]

GLP-1-derived nonapeptide GLP-1(28-36) amide inhibits weight gain and attenuates diabetes and hepatic steatosis in diet-induced obese mice